Senseonics (NYSE:SENS) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Senseonics (NYSE:SENS) in a research report issued on Thursday. The firm set a “sell” rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $2.00 price target on shares of Senseonics in a research note on Friday, November 15th.

Senseonics Stock Up 1.1 %

Shares of SENS opened at $0.59 on Thursday. The stock has a market capitalization of $352.55 million, a price-to-earnings ratio of -4.56 and a beta of 0.77. Senseonics has a 52 week low of $0.25 and a 52 week high of $0.75. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. The stock has a fifty day moving average of $0.35 and a 200-day moving average of $0.38.

Insider Buying and Selling at Senseonics

In related news, CEO Timothy T. Goodnow bought 315,000 shares of Senseonics stock in a transaction that occurred on Tuesday, December 10th. The shares were acquired at an average cost of $0.31 per share, for a total transaction of $97,650.00. Following the completion of the acquisition, the chief executive officer now directly owns 11,310,355 shares of the company’s stock, valued at approximately $3,506,210.05. The trade was a 2.86 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Frederick T. Sullivan bought 124,933 shares of the firm’s stock in a transaction on Thursday, December 12th. The shares were purchased at an average cost of $0.38 per share, with a total value of $47,474.54. Following the transaction, the chief financial officer now directly owns 2,478,844 shares in the company, valued at approximately $941,960.72. This trade represents a 5.31 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Senseonics

A number of hedge funds have recently bought and sold shares of the company. FMR LLC grew its holdings in Senseonics by 48,267.2% during the 3rd quarter. FMR LLC now owns 168,318 shares of the company’s stock worth $59,000 after acquiring an additional 167,970 shares during the period. GSA Capital Partners LLP bought a new stake in shares of Senseonics during the 3rd quarter valued at about $117,000. Symmetry Partners LLC acquired a new stake in Senseonics during the third quarter worth approximately $164,000. Cubist Systematic Strategies LLC increased its holdings in Senseonics by 25.9% in the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after purchasing an additional 85,501 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Senseonics by 3.2% in the third quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock valued at $2,042,000 after buying an additional 179,103 shares during the period. Institutional investors own 12.36% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.